
Munear T. Akki
Examiner (ID: 8967, Phone: (571)272-3428 , Office: P/2682 )
| Most Active Art Unit | 2687 |
| Art Unit(s) | 2682, 2687 |
| Total Applications | 693 |
| Issued Applications | 613 |
| Pending Applications | 2 |
| Abandoned Applications | 88 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20218692
[patent_doc_number] => 20250281623
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-09-11
[patent_title] => HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE
[patent_app_type] => utility
[patent_app_number] => 19/073111
[patent_app_country] => US
[patent_app_date] => 2025-03-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 77332
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19073111
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/073111 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | Mar 6, 2025 | Pending |
Array
(
[id] => 19554762
[patent_doc_number] => 20240366554
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-07
[patent_title] => (9BETA-H)-PIMARANE MOTHER NUCLEUS DITERPENOID COMPOUND WITH ANTI-COLON CANCER ACTIVITY AND DERIVATIVE THEREOF, AND PREPARATION METHOD THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/738089
[patent_app_country] => US
[patent_app_date] => 2024-06-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4733
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18738089
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/738089 | (9beta-H)-pimarane mother nucleus diterpenoid compound with anti-colon cancer activity and derivative thereof, and preparation method thereof | Jun 9, 2024 | Issued |
Array
(
[id] => 19112735
[patent_doc_number] => 20240124485
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-18
[patent_title] => SUBSTITUTED AMIDE MACROCYCLIC COMPOUNDS WITH OREXIN-2 RECEPTOR AGONIST ACTIVITY
[patent_app_type] => utility
[patent_app_number] => 18/376020
[patent_app_country] => US
[patent_app_date] => 2023-10-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28786
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -36
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18376020
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/376020 | SUBSTITUTED AMIDE MACROCYCLIC COMPOUNDS WITH OREXIN-2 RECEPTOR AGONIST ACTIVITY | Oct 2, 2023 | Pending |
Array
(
[id] => 19876863
[patent_doc_number] => 20250109120
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-04-03
[patent_title] => INDOLINE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF TUMOR OR CELL PROLIFERATIVE AND FIBROSIS DISEASES
[patent_app_type] => utility
[patent_app_number] => 18/477022
[patent_app_country] => US
[patent_app_date] => 2023-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14677
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 341
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18477022
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/477022 | INDOLINE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF TUMOR OR CELL PROLIFERATIVE AND FIBROSIS DISEASES | Sep 27, 2023 | Pending |
Array
(
[id] => 18938117
[patent_doc_number] => 20240033256
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-01
[patent_title] => INHIBITORS OF POSITIVE STRAND RNA VIRUSES
[patent_app_type] => utility
[patent_app_number] => 18/374326
[patent_app_country] => US
[patent_app_date] => 2023-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4972
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 174
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18374326
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/374326 | INHIBITORS OF POSITIVE STRAND RNA VIRUSES | Sep 27, 2023 | Pending |
Array
(
[id] => 19157655
[patent_doc_number] => 20240150362
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-09
[patent_title] => Substituted Pyrrolotriazines
[patent_app_type] => utility
[patent_app_number] => 18/455978
[patent_app_country] => US
[patent_app_date] => 2023-08-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 76000
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -45
[patent_words_short_claim] => 1013
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18455978
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/455978 | Substituted Pyrrolotriazines | Aug 24, 2023 | Pending |
Array
(
[id] => 19332676
[patent_doc_number] => 20240247106
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-25
[patent_title] => BIODEGRADABLE DRUG-POLYMER CONJUGATE
[patent_app_type] => utility
[patent_app_number] => 18/226713
[patent_app_country] => US
[patent_app_date] => 2023-07-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38824
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18226713
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/226713 | Biodegradable drug-polymer conjugate | Jul 25, 2023 | Issued |
Array
(
[id] => 18921251
[patent_doc_number] => 20240024255
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-25
[patent_title] => CURCUMINOID COMPOSITION WITH ENHANCED BIOAVAILABILITY AND METHODS THEREFOR
[patent_app_type] => utility
[patent_app_number] => 18/225612
[patent_app_country] => US
[patent_app_date] => 2023-07-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17717
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18225612
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/225612 | CURCUMINOID COMPOSITION WITH ENHANCED BIOAVAILABILITY AND METHODS THEREFOR | Jul 23, 2023 | Pending |
Array
(
[id] => 18550718
[patent_doc_number] => 20230248718
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-10
[patent_title] => PHARMACEUTICAL COMBINATION OF ANTISPASMODIC AND ANXIOLYTIC AGENT
[patent_app_type] => utility
[patent_app_number] => 18/107619
[patent_app_country] => US
[patent_app_date] => 2023-02-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9363
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18107619
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/107619 | PHARMACEUTICAL COMBINATION OF ANTISPASMODIC AND ANXIOLYTIC AGENT | Feb 8, 2023 | Pending |
Array
(
[id] => 18522882
[patent_doc_number] => 20230233531
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => USE OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS FOR TREATMENT OF INFLAMMATION
[patent_app_type] => utility
[patent_app_number] => 18/158717
[patent_app_country] => US
[patent_app_date] => 2023-01-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10505
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 149
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18158717
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/158717 | USE OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS FOR TREATMENT OF INFLAMMATION | Jan 23, 2023 | Pending |
Array
(
[id] => 19097649
[patent_doc_number] => 20240116877
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-11
[patent_title] => KIT KINASE INHIBITORS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/073721
[patent_app_country] => US
[patent_app_date] => 2022-12-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 62885
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -40
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18073721
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/073721 | KIT KINASE INHIBITORS AND METHODS OF USE THEREOF | Dec 1, 2022 | Pending |
Array
(
[id] => 18509948
[patent_doc_number] => 20230226040
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-20
[patent_title] => COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 17/991482
[patent_app_country] => US
[patent_app_date] => 2022-11-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26429
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -66
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17991482
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/991482 | COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR | Nov 20, 2022 | Pending |
Array
(
[id] => 18360127
[patent_doc_number] => 20230141718
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-11
[patent_title] => METHODS OF TREATING GLIOBLASTOMA
[patent_app_type] => utility
[patent_app_number] => 17/983732
[patent_app_country] => US
[patent_app_date] => 2022-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14190
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -42
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17983732
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/983732 | METHODS OF TREATING GLIOBLASTOMA | Nov 8, 2022 | Abandoned |
Array
(
[id] => 17790334
[patent_doc_number] => 20220249425
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-11
[patent_title] => METHODS FOR TREATING BREAST CANCER
[patent_app_type] => utility
[patent_app_number] => 17/659121
[patent_app_country] => US
[patent_app_date] => 2022-04-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4418
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17659121
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/659121 | METHODS FOR TREATING BREAST CANCER | Apr 12, 2022 | Pending |
Array
(
[id] => 19246708
[patent_doc_number] => 20240197692
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => Combination Comprising Everolimus and Amcenestrant
[patent_app_type] => utility
[patent_app_number] => 18/286496
[patent_app_country] => US
[patent_app_date] => 2022-04-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3746
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18286496
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/286496 | Combination Comprising Everolimus and Amcenestrant | Apr 11, 2022 | Pending |
Array
(
[id] => 19570298
[patent_doc_number] => 20240374590
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-14
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 18/286469
[patent_app_country] => US
[patent_app_date] => 2022-04-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22895
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -93
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18286469
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/286469 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Apr 10, 2022 | Pending |
Array
(
[id] => 19232093
[patent_doc_number] => 20240189284
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => COMPOSITION FOR PROMOTING LIPOLYSIS
[patent_app_type] => utility
[patent_app_number] => 18/286446
[patent_app_country] => US
[patent_app_date] => 2022-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3876
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18286446
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/286446 | COMPOSITION FOR PROMOTING LIPOLYSIS | Mar 24, 2022 | Pending |
Array
(
[id] => 17655250
[patent_doc_number] => 20220175715
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-09
[patent_title] => CARBOPLATIN COMPLEX AND PHARMACEUTICAL PREPARATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/681197
[patent_app_country] => US
[patent_app_date] => 2022-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10242
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17681197
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/681197 | CARBOPLATIN COMPLEX AND PHARMACEUTICAL PREPARATION THEREOF | Feb 24, 2022 | Pending |
Array
(
[id] => 18987692
[patent_doc_number] => 20240059661
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-22
[patent_title] => SOLID STATE FORMS OF 2-(3,5-DICHLOROPHENYL)-1,3-BENZOXAZOLE-6-CARBOXYLIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND POLYMORPHS THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/548691
[patent_app_country] => US
[patent_app_date] => 2022-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11672
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18548691
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/548691 | SOLID STATE FORMS OF 2-(3,5-DICHLOROPHENYL)-1,3-BENZOXAZOLE-6-CARBOXYLIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND POLYMORPHS THEREOF | Feb 24, 2022 | Pending |
Array
(
[id] => 18878981
[patent_doc_number] => 20240002350
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-04
[patent_title] => PROTEIN AND LIPID THERAPEUTIC TARGETS
[patent_app_type] => utility
[patent_app_number] => 18/037406
[patent_app_country] => US
[patent_app_date] => 2021-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25783
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18037406
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/037406 | PROTEIN AND LIPID THERAPEUTIC TARGETS | Nov 16, 2021 | Pending |